








Targeting the *PPP2R2A* tumor suppressor in Prostate Cancer

Hemizygous deletion of the PP2A activator *PPP2R2A* in prostate cancer is associated with increased tumor grade, metastasis and reduced disease-free survival: Its reconstitution suppresses tumorigenicity *in vitro* and animal models



Xavier Graña, PhD
Professor, Fels Cancer Institute for Personalized Medicine
Cancer Biology and Genetics
Cluster Director

Selected publications:

Zhao Z, et al. (2019).

Oncogenesis 8(12):72. doi:

10.1038/s41389-019-0180-9

Zhao Z (2020) *Prostate Cancer*

Prostatic Dis. 24(1):233-

243. doi: 10.1038/s41391-

020-00274-4.

Fowle H, et al (2021) *BioRxiv*

[https://doi.org/10.1101/2021.](https://doi.org/10.1101/2021.03.02.433577)

[03.02.433577](https://doi.org/10.1101/2021.03.02.433577)

Supported by:

NIH R01 GM117437